Send to

Choose Destination
Lipids Health Dis. 2017 Dec 27;16(1):253. doi: 10.1186/s12944-017-0617-0.

Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol.

Author information

Department of Community Health and Behavior Medicine, School of Public Health, Shanghai Jiao Tong University, Shanghai, 200025, People's Republic of China.
Imaging Institute of Rehabilitation and Development of Brain Function, the Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, 637000, People's Republic of China.
Lotus LLC, John Hopkins University-MCC, 9601 Medical Center Drive, Rockville, MD, 20850, USA.
Department of Community Health and Behavior Medicine, School of Public Health, Shanghai Jiao Tong University, Shanghai, 200025, People's Republic of China.
Department of Community Health and Family Medicine, Shanghai Jiao Tong University School of Public Health, Shanghai, 200025, People's Republic of China.
Tang Qiao Community Health Service Center, Pudong New District, Shanghai, 200127, People's Republic of China.
Biochemistry Program, University of Maryland, Baltimore, MD, 21201, USA.
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
School of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.



To study the effects of supplementation of a marine omega-3 poly-unsaturated fatty acids (n3-PUFA) formulation (Omega3Q10) in older adults with hypertension and/or hypercholesterolemia.


A total of 97 people were enrolled to receive 12-week supplementation of either Omega3Q10 (n = 48) or soybean oil (n = 49). Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and hypertension-related symptoms were determined before and after the supplementation.


There were no baseline differences between the two groups. Omega3Q10 supplementation significantly reduced diastolic blood pressure (DBP) (from 81.6 ± 5.3 mmHg to 79.3 ± 5.2 mmHg, P < 0.05). Blood concentrations of TC and LDL-C decreased significantly and blood HDL-C level increased significantly after 12 weeks of Omega3Q10 (5.5 ± 0.7 vs. 5.3 ± 0.5, P < 0.05; 3.7 ± 0.8 vs. 3.3 ± 0.6, P < 0.05; 1.2 ± 0.6 vs. 1.3 ± 0.5, P < 0.05, respectively) and soybean oil supplementation (5.7 ± 0.8 vs. 5.6 ± 0.7, P < 0.05; 3.6 ± 0.7 vs. 3.4 ± 0.8, P < 0.05; 1.0 ± 0.8 vs. 1.2 ± 0.7, P < 0.05, respectively) but no group differences were found. A significantly greater proportion of the people in the Omega3Q10 group became free from headache and palpitations & chest tightness symptoms after the 12-week supplementation compared to that of the soybean oil group (95.5% vs. 71.4%, P < 0.01; 95.8 vs. 75.5%, P < 0.01, respectively).


12-week supplementation of Fish oil-based PUFA appear to be more effective in improving DBP and hypertension-related symptoms than soybean oil in old adults with hypertension and hypercholesterolemia although both supplementation improved TC, LDL-C and HDL-C concentrations.


Blood pressures, Dyslipidemia, Old adults; Fish oil-derived PUFA; Soybean oil

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center